Mark R. Hake

CFA

Mark R. Hake, CFA is a financial analyst and entrepreneur. He has been a Chartered Financial Analyst (CFA) for 31 years and has owned his own investment management and investment research firms that focused on value stocks, both in the U.S. and overseas.

Mark writes over 600 articles per year on stocks, cryptos, SPACs, convertibles, ETFs, and other financial securities. He has been ranked with 5 stars by TipRanks.com (under “Mark R. Hake”) with an average return of over 22% annually and #36 out of 8,116 writers. Presently he authors articles on Medium.com and other sites.

Mark also invests in public and private equities and has acted as a hedge fund manager and portfolio manager for various money management firms. He has also acted as CFO and Chief Strategy Officer for several fin-tech and software companies.

You can follow Mark on LinkedIn and on TipRanks .

Recent Articles

After Forming a Base AMP Crypto Looks Set to Move Higher Again

By Mark R. Hake, CFA Feb 17, 2022

After Forming a Base AMP Crypto Looks Set to Move Higher Again. AMP crypto could benefit from the rising base of payment partners and locations using its collateral and staking system.

Polestar Should Be a Hit When its Reverse Merger with Gores Guggenheim Closes

By Mark R. Hake, CFA Feb 17, 2022

GGPI stock is worth at least 59% more and could hit $19 per share once the reverse merger with Polestar goes through in 2022.

OneMain Is a Rare Bargain With a Well-Covered 7% Dividend Yield

By Mark R. Hake, CFA Feb 17, 2022

OMF stock has a 7.1% dividend yield and an 11.3% prospective buyback yield, giving it an astounding 18% total yield for shareholders.

Don’t Expect Skillz to Rise Until It Can Show Profits

By Mark R. Hake, CFA Feb 16, 2022

Skillz will release Q4 earnings on Feb. 23, but don't expect SKLZ stock to move much higher until the company gets on track to make money.

Novavax Just Can’t Get it Together

By Mark R. Hake, CFA Feb 16, 2022

Patient investors should wait for NVAX stock to hit another low or for the FDA to approve its Covid-19 vaccine before investing.